智通财经网·2026-01-12 09:03Group 1 - The company expects a revenue increase of approximately 15.84% for the fiscal year ending December 31, 2025, with projected revenue of about RMB 45,456.17 million [1] - The adjusted net profit attributable to shareholders is anticipated to be around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1] - The net profit attributable to shareholders is projected to reach approximately RMB 19.151 billion, representing a significant year-on-year increase of about 102.65% [1] Group 2 - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model, enhancing capabilities and optimizing production processes to drive steady growth [2] - Non-recurring profit items impacting net profit include expected net gains of approximately RMB 4.161 billion from the sale of part of its stake in WuXi XDC Cayman Inc. and about RMB 1.434 billion from the sale of 100% stakes in two clinical research companies [2]